Treating progressive multiple sclerosis, a chronic neurological condition characterized by ongoing disability accumulation, presents significant challenges due to its complex nature and limited therapeutic options.

Multiple sclerosis (MS) is a chronic autoimmune disorder that affects the central nervous system, leading to inflammation, damage to myelin (the protective covering of nerve fibers), and neurodegeneration [3, 4, 5]. While many people with MS experience periods of relapse and remission, a significant number face progressive forms of the disease, where neurological disability steadily worsens over time [3, 4]. Managing progressive MS is considered one of the major challenges in contemporary neurology, demanding new approaches to treatment and care [1].

Understanding Progressive Multiple Sclerosis

MS is characterized by the immune system mistakenly attacking the central nervous system, leading to inflammation and demyelination [4, 5]. Over time, this damage results in neuroaxonal and synaptic loss, which is a major cause of long-term disability [3, 4]. Progressive forms of MS are broadly categorized into primary progressive MS (PPMS) and secondary progressive MS (SPMS).

Primary Progressive MS (PPMS): Affects about 10-15% of people with MS and is characterized by a steady worsening of neurological function from the onset, without early relapses or remissions [2].
Secondary Progressive MS (SPMS): Occurs after an initial period of relapsing-remitting MS (RRMS), where the disease course transitions to one of continuous progression, often with fewer or no relapses [7].

It has become increasingly clear that elements of progression are a dominant factor in accumulating MS-related neurological disability across all clinical courses, detectable throughout the disease trajectory [3].

Challenges in Diagnosis and Management

Despite significant advancements in treating relapsing forms of MS, treatment options for progressive forms remain limited [4]. This scarcity of effective immunotherapeutic and management options contributes to a substantial physical and psychological burden for individuals with progressive MS [2]. Diagnosis can also be challenging; PPMS is often diagnosed with a delay, and the transition from RRMS to SPMS can be ambiguous, leading to diagnostic delays [2, 7]. The underlying neurodegeneration, which drives much of the disability, often goes undetected until significant neurological impairment has already occurred [7]. Furthermore, a complete understanding of the disease mechanisms and adequate translational models for progressive MS are still lacking, hindering the development of new therapies [5].

Current Therapeutic Approaches

Current therapeutic strategies for progressive MS aim to address different aspects of the disease pathophysiology. These include:

Anti-inflammatory therapies: Medications like ocrelizumab and siponimod work by modulating the immune system to reduce inflammation [1]. Anti-CD20 monoclonal antibodies, such as rituximab, ocrelizumab, and ofatumumab, have shown effectiveness in reducing disease activity and slowing progression, particularly in PPMS [5].
Remyelinating strategies: These therapies aim to repair the damaged myelin sheath around nerve fibers. Opicinumab is an example of a drug being explored for its remyelinating potential [1].
Neuroprotective agents: These treatments focus on protecting nerve cells from damage and degeneration. Examples include high-dose biotin, ibudilast, and simvastatin [1].

Beyond disease-modifying therapies, comprehensive symptom management and lifestyle support are crucial for maintaining quality of life and reducing disability in people with progressive MS [4].

Promising Perspectives and Emerging Therapies

A growing understanding of the pathophysiology of progressive MS, particularly the role of compartmentalized inflammation within the central nervous system and associated neurodegenerative processes, is leading to the development of new targeted immunomodulatory treatments [3, 6]. Researchers are actively exploring several promising avenues:

Bruton's tyrosine kinase (BTK) inhibitors: These emerging therapies aim to modulate microglia and B cell pathology, which are implicated in CNS inflammation [5, 6].
CD40-CD40L blockade: This strategy targets specific immune pathways involved in inflammation and disease progression [6].
CD19-directed CAR-T cells: A novel cell-based therapy that harnesses the body's immune cells to target specific components of the disease [6].
Agents promoting remyelination: Continued research into therapies that can repair myelin damage offers hope for restoring nerve function [5].

These emerging therapies increasingly target the inflammation within the central nervous system that drives progression independent of relapse activity [6]. New methodological approaches for therapeutic protocols and adaptable outcomes to assess progression are still needed to advance treatment development [1]. The lessons learned from developing disease-modifying therapies for MS are also informing efforts to find similar treatments for other neurological disorders, such as Parkinson's disease [8].

Sources

This article summarises published research for a general audience. It is not medical advice — talk to a qualified clinician about your own situation. Need help finding one? Browse doctors.

Navigating Progressive Multiple Sclerosis Treatment Challenges

Understanding Progressive Multiple Sclerosis

Challenges in Diagnosis and Management

Current Therapeutic Approaches

Promising Perspectives and Emerging Therapies

Sources